Ascendia Joins the Fight Against COVID-19; Developing Formulations
Ascendia Pharmaceuticals, a specialty CDMO company engaged in the design, formulation, optimization, and manufacture of poorly soluble molecules for various dosage forms with patent-protected technology platforms, recently announced it is engaged in multiple collaborations to develop and prepare injectable, inhalation, and oral formulations to combat the coronavirus crisis.
Founder and CEO Dr. Jim Huang said “We are very excited to apply our technologies to develop medicines for COVID-19, and are extremely proud of our colleagues for their dedication, professionalism, and most importantly, practicing social distancing well to stay safe, while maintaining business continuity to meet the demands of our clients and to exceed their expectations by making the impossible, possible.”
Ascendia is a specialty CDMO company dedicated to developing enhanced formulations of existing drug products, and enabling formulations for preclinical- and clinical-stage drug candidates. Ascendia specializes in improving the bioavailability of poorly water-soluble drugs using its nano-particle- and nano-emulsion-based technologies. Ascendia formulates products for injection (IV, SC, or IM), transdermal, ophthalmic, nasal delivery, and controlled-release products. The company has three technology platforms – EmulSol for producing nano-emulsions, AmorSol for creating amorphous solid dispersions, and NanoSol for formulating nano-particles. For more information, visit www.ascendiapharma.com or call (732) 640-0058.
Contacts
Ascendia Pharmaceuticals
661 US Highway One
North Brunswick, NJ 08902
Robert J. Bloder, CBO (732) 640-0058
robert.bloder@ascendiapharma.com
Total Page Views: 1113
